FDA accepts for priority review Bristol-Myers Squibb’s application for Opdivo plus Yervoy in first-line NSCLC
The FDA has granted the application Priority Review with a Prescription Drug User Fee Act (PDUFA) goal date of May 15, 2020. “The FDA’s acceptance of our application